SCHEMBL7420286

SCHEMBL7420286

CC(=O)OCC1CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 7/20 0.42
CHRM1 P11229 7/20 0.42
CHRM3 P20309 7/20 0.42
ALOX15 P16050 1/20 0.42
TDP1 Q9NUW8 1/20 0.40
GABRA5 P31644 3/20 0.39
GABRB2 P47870 3/20 0.39
SLC6A1 P30531 2/20 0.39
SLC6A12 P48065 2/20 0.39
SLC6A11 P48066 2/20 0.39
SLC6A13 Q9NSD5 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRA4 P48169 2/20 0.39
GABRR1 P24046 1/20 0.39
CPN1 P15169 1/20 0.38
CPB2 Q96IY4 1/20 0.38
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
F2R P25116 1/20 0.37
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7420281 0.98 TDP1 (0.42) CHRM2CHRM1CHRM3ALOX15TDP1
Hydrochloric Acid SCHEMBL27470440 0.98 TDP1 (0.42) CHRM2CHRM1CHRM3ALOX15TDP1
Benzene SCHEMBL3357152 0.94 CHRM3 (0.49) CHRM2CHRM1CHRM3ALOX15TDP1
SCHEMBL3325494 0.88 SLC6A1 (0.50) CHRM3ALOX15GABRA5GABRB2SLC6A1
SCHEMBL17029138 0.84 ALDH1A1 (0.43) CHRM2CHRM1CHRM3TSHR
SCHEMBL5696892 0.84 ALDH1A1 (0.43) CHRM2CHRM1CHRM3TSHR
SCHEMBL6256094 0.84
SCHEMBL27271725 0.83 ALDH1A1 (0.46) CHRM2CHRM1CHRM3ALOX15TDP1
Hydrochloric Acid SCHEMBL28064641 0.82
SCHEMBL22856596 0.81 LMNA (0.37) CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1738805-A N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivatives and related compounds use as CGRP-antagonists for treating a headache BOEHRINGER INGELHEIM INT (DE) 2006-02-22 CN claimed
US-20230218597-A1 SUBSTITUTED PYRIDINES AND METHODS OF USE THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-07-13 US disclosed
US-20230218597-A1 SUBSTITUTED PYRIDINES AND METHODS OF USE THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-07-13 US disclosed
US-11590116-B2 Substituted pyridines and methods of use THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-02-28 US disclosed
WO-2021102468-A1 SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-05-27 WO disclosed
US-20210154179-A1 SUBSTITUTED PYRIDINES AND METHODS OF USE THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-05-27 US disclosed
US-10858339-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2020-12-08 US disclosed
WO-2017070229-A1 PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-04-27 WO disclosed
CN-104710408-A Chiral cis-imidazolines HOFFMANN LA ROCHE 2015-06-17 CN disclosed
CN-104487435-A Benzodioxanes in combination with other actives for inhibiting leukotriene production BOEHRINGER INGELHEIM INT 2015-04-01 CN disclosed
CN-102159207-A Substituted pyrrolidine-2-carboxamides HOFFMANN LA ROCHE 2011-08-17 CN disclosed
EP-2322536-A2 Aminothiazole derivatives and their uses as antibacterial agents Novartis AG (CH) 2011-05-18 EP disclosed
CN-101835757-A Diacylglycerol acyltransferase inhibitors HOFFMANN LA ROCHE 2010-09-15 CN disclosed
CN-101821251-A Chiral cis-imidazolines HOFFMANN LA ROCHE 2010-09-01 CN disclosed
CN-101180291-A As 5-HT4Benzimidazole carboxamide compounds as receptor agonists THERAVANCE INC (US) 2008-05-14 CN disclosed
CN-1738805-A N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivatives and related compounds use as CGRP-antagonists for treating a headache BOEHRINGER INGELHEIM INT (DE) 2006-02-22 CN disclosed
CN-1418193-A heterocyclic side chain containing metalloprotease inbibitors PROCTER & GAMBLE (US) 2003-05-14 CN disclosed
EP-0815103-A1 TRYPSIN AND THROMBIN INHIBITORS Novartis AG (CH) 1998-01-07 EP disclosed
WO-1996029327-A1 TRYPSIN AND THROMBIN INHIBITORS NOVARTIS AG (CH) 1996-09-26 WO disclosed
CN-1131665-A Piperazine derivatives, medicaments comprising these compounds, their use and processes for their preparation THOMAE GMBH DR K (DE) 1996-09-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210154179-A1 SUBSTITUTED PYRIDINES AND METHODS OF USE ALK, ACVR1, ACVR2A CHRM2 1014/4885CHRM1 1818/4885CHRM3 406/4885
US-10858339-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds UACA, HRAS, MYLK CHRM2 4567/4885CHRM1 4676/4885CHRM3 4326/4885
US-20230218597-A1 SUBSTITUTED PYRIDINES AND METHODS OF USE ALK, ACVR1, ACVR2A CHRM2 1014/4885CHRM1 1818/4885CHRM3 406/4885
US-11590116-B2 Substituted pyridines and methods of use ALK, ACVR1, ACVR2A CHRM2 1014/4885CHRM1 1818/4885CHRM3 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.